Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05758701 · ClinicalTrials.gov registry record · Phase 4
CT TAVR Abdomen Study
A Phase 4 study of Transcatheter Aortic Valve Replacement, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 164
- Enrollment target
- 1
- Study location
NCT05758701: Recruiting Phase 4 study of Transcatheter Aortic Valve Replacement, sponsored by University of Maryland, Baltimore.
NCT05758701 is a Phase 4 study of Transcatheter Aortic Valve Replacement that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 164 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05758701, a Phase 4 study of Transcatheter Aortic Valve Replacement, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 164 participants
- Enrollment target
- 1
- Study location
Study Summary
A standard polyenergetic CT (computed tomography) procedure utilizes 100 ml of iodinated contrast. A recent world-wide shortage of iodine based intravenous contrast has highlighted the need to search for alternative methods or doses. Reducing iodinated IV contrast dose can mitigate IV contrast supply shortages and enable significant cost savings for the radiology practice and hospital system. In addition, decreased IV contrast dose can potentially reduce the rate of acute kidney injury, specifically in patients with decreased renal function. The purpose of the study is to determine whether low IV contrast dose CT with monoenergetic reconstruction can be use for presurgical planning of transcatheter valve replacement (TAVR) procedure.
Primary Outcome
5-point Likert Scale
Conditions Studied
Interventions
- COMBINATION_PRODUCT Iodinated Contrast Agent (Omnipaque)
- DEVICE Dual Energy CT
Study Locations (1)
Maryland
- University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2023-09-19 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 4 |
What NCT05758701 shows while recruiting
NCT05758701 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Transcatheter Aortic Valve Replacement appearing as the primary indexed condition, and to 2 interventions - of which Iodinated Contrast Agent (Omnipaque) is the first listed.
NCT05758701 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05758701 about?
NCT05758701 is a clinical study titled "CT TAVR Abdomen Study". A standard polyenergetic CT (computed tomography) procedure utilizes 100 ml of iodinated contrast. A recent world-wide shortage of iodine based intravenous contrast has highlighted the need to search for alternative methods or doses. Reducing iodinated IV contrast dose can mitigate IV contrast suppl...
What is the current status of trial NCT05758701?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 164 participants. The study started on 2023-09-19. Estimated completion is 2027-03-01.
What conditions does trial NCT05758701 study?
This clinical trial studies the following conditions: Transcatheter Aortic Valve Replacement.
What interventions are being tested in trial NCT05758701?
The interventions under investigation include: Iodinated Contrast Agent (Omnipaque) (COMBINATION_PRODUCT), Dual Energy CT (DEVICE).
Who is sponsoring clinical trial NCT05758701?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05758701 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transcatheter Aortic Valve Replacement
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05758701's enrollment target sits among peer trials
164 496th of 2000 higher than 1,501 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI